6505--Bumetanide Tablets (VA-26-00011200)
ID: 36E79725R0068Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/e49c3a41aa45408796ab3fbff34f74dc/view
Timeline
    Description

    The Department of Veterans Affairs (VA) is seeking proposals for the supply of Bumetanide Tablets through its Pharmaceutical Prime Vendor (PPV) Programs, which will serve VA, Department of Defense (DoD), Indian Health Service (IHS), and Bureau of Prisons (BOP) facilities. The contract will consist of a one-year base period with four additional one-year options, requiring offerors to provide pricing for all five line items and option years, including a 0.5% Cost Recovery Fee. Bumetanide Tablets are critical medications used in the treatment of various medical conditions, and compliance with FDA cGMP standards, unique NDC numbers, barcoding requirements, and the Drug Supply Chain Security Act (DSCSA) is mandatory for successful bidders. Interested parties should note that the deadline for submitting proposals has been extended to November 20, 2025, at 2:30 PM CT, and may contact Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further information.

    Point(s) of Contact
    Andrew J CazaresContract Specialist
    Andrew.Cazares@va.gov
    Files
    Title
    Posted
    36E79725R0068 0001.docx
    The Department of Veterans Affairs (VA) National Acquisition Center issued Amendment 0001 to Solicitation 36E79725R0068, extending the deadline for receipt of offers. The original deadline of November 13, 2025, has been extended to November 20, 2025, at 2:30 PM CT. All other terms and conditions of the solicitation remain unchanged. This amendment, signed by Contracting Officer Andrew J. Cazares, ensures that potential offerors have additional time to submit their proposals for this federal government RFP.
    36E79725R0068_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center intends to issue an unrestricted Request for Proposal (RFP) 36E79725R0068 for Bumetanide Tablets. This procurement aims to secure an uninterrupted supply for the VA (including Consolidated Mail Order Pharmacies and State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be for one year with four optional one-year periods, with distribution through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique NDC numbers and labels. The solicitation is expected around October 30, 2025, with a tentative closing date of November 13, 2025. The estimated annual requirements include various dosages and package sizes of Bumetanide tablets. All interested parties should monitor sam.gov for updates, and inquiries can be directed to Andrew J. Cazares.
    36E79725R0068.docx
    This government solicitation (36E79725R0068) outlines a Request for Proposal (RFP) from the Department of Veterans Affairs (VA) for Bumetanide Tablets, to be supplied through Pharmaceutical Prime Vendor (PPV) Programs for VA, DoD, IHS, and BOP facilities. The contract will be a one-year base period with four one-year options. Offerors must provide prices for all five line items and all option years, including a 0.5% Cost Recovery Fee. Key requirements include adherence to FDA cGMP status, unique 11-digit NDC numbers for products, barcoding standards (GS1-128 or HIBCC), and compliance with the Drug Supply Chain Security Act (DSCSA). Successful contractors must establish business-to-business agreements with PPVs and adhere to strict backorder protocols. Offers for "covered drugs" must have an existing Master Agreement and Pharmaceutical Pricing Agreement with the VA.
    Lifecycle
    Title
    Type
    6505--Bumetanide Tablets (VA-26-00011200)
    Currently viewing
    Solicitation
    6505--Bumetanide Tablets (VA-26-00011200)
    Presolicitation
    Similar Opportunities
    6505--Zonisamide Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the unrestricted procurement of Zonisamide Capsules, which will serve various federal entities including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will be awarded to a single offeror capable of providing an uninterrupted supply of the specified medications, with a contract period of one year and four optional one-year extensions. The procurement is critical for ensuring the availability of these pharmaceutical products, which are essential for patient care within the VA and other federal health facilities. Interested parties should monitor SAM.gov for the solicitation, expected to be issued around December 15, 2025, with a closing date of December 30, 2025, and may direct inquiries to Chris Carthron at Christopher.Carthron@va.gov.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    VISN 21 Lenalidomide Capsules Multiple Strengths (Generic)
    Buyer not available
    The Department of Veterans Affairs (VA) is conducting a Sources Sought notice to identify vendors capable of supplying Lenalidomide Capsules in multiple strengths, specifically for VISN 21, which includes locations in California, Hawaii, Nevada, and Manila, Philippines. The contractor must be a Certified Lenalidomide REMS Pharmacy, licensed in the applicable states, and comply with all relevant federal, state, and VA regulations, including USP <800> for hazardous drugs. This procurement is critical as Lenalidomide is an oral anti-cancer medication, and the contract will span five one-year ordering periods from March 1, 2026, to February 28, 2031, requiring timely and compliant delivery of FDA-approved products. Interested vendors should submit their capability statements and relevant information to David J. Alvarez at david.alvarez4@va.gov by 10:00 AM Pacific Time on December 10, 2025.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    DA01--550-26-1-985-0034 InstyMed Dispenser System (VA-26-00024776)
    Buyer not available
    The Department of Veterans Affairs (VA) intends to negotiate a limited source contract for the InstyMed Dispenser System, identified by Solicitation Number 36C25226Q0106. This procurement includes the purchase of the dispenser system and professional installation services, emphasizing that it is not a request for proposal or quote, as no solicitation document is available. The InstyMed Dispenser System is crucial for enhancing medication delivery and management within VA facilities. Interested parties must respond to this notice by December 12, 2025, at 10:00 am CST, and can contact Contracting Officer Vernise L. Newton at vernise.newton@va.gov or by phone at 414-844-4850 for further information.
    InstyMed Dispenser System
    Buyer not available
    The Department of Veterans Affairs is issuing a modification to its previous notice regarding the InstyMed Dispenser System, indicating its intent to negotiate a limited source contract. This modification serves to establish a deadline for responses, emphasizing the urgency and specificity of the procurement process. The InstyMed Dispenser System is crucial for enhancing healthcare delivery to veterans, ensuring efficient medication dispensing and management. Interested parties must submit their responses by December 12, 2025, at 10:00 am CST, and can direct inquiries to Contracting Officer Vernise L. Newton at vernise.newton@va.gov or by phone at 414-844-4850.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.